Publications @Google Scholar

 TOP CAR with TMIGD2 as a safe and effective costimulatory domain in CAR cells treating human solid tumors 

Nishimura CD, Corrigan D, Zheng XY, Galbo Jr PM, Wang S, Liu Y, Wei Y, Suo L, Cui W, Mercado N, Zheng D, Zhang CC,  Zang X.

Science Advances, 10:eadk1857, 2024

TMIGD2 is an orchestrator and therapeutic target on human acute myeloid leukemia stem cells 

Wang H, Sica RA, Kaur G, Galbo Jr PM, Jing Z, Nishimura CD, Ren X, Tanwar A, Etemad-Gilbertson B, Will B, Zheng D, Fooksman D,  Zang X.

Nature Communications, 15:11. doi: 10.1038/s41467-023-43843-6, 2024

Functional contribution and clinical implication of cancer-associated fibroblasts in Glioblastoma 

Galbo Jr PM, Madsen AT, Liu Y, Peng M, Wei Y, Ciesielski MJ, Fenstermaker RA, Graff S, Montagna C, Segeal JE, Sidoli S,  

Zang X*, Zheng D*.

Clinical Cancer Research, 30:865-876, 2024

A galectin-9-driven CD11chigh decidual macrophage subset suppresses uterine vascular remodeling in preeclampsia

Li Y, Sang Y, Chang Y, Xu C, Lin Y, Zhang Y, Chiu P, Yeung W, Zhou H, Dong N, Xu L, Chen J, Zhao W, Liu L, Yu D, Zang X, Ye J, Yang J, Wu Q, Li DJ, Wu L, Du M.

Circulation, 149:1670-1688, 2024

Macrophage plasticity and function in cancer and pregnancy

Yin T, Li X, Li Y, Zang X, Liu L, Du M.

Frontiers in Immunology, 14:1333549, 2024

A SOX9-B7x axis safeguards dedifferentiated cells from immune surveillance to drive breast cancer progression

Liu Y, John P, Christin JR, Nishimura CD, Couturier N, Ren X, Galbo P, Wei Y, Pulanco MC, Cui J, Cui W, Bartholdy BA, Zheng D, Lauvau G, Oktay MH

Zang X*, Guo W*.

Developmental Cell, 58:2700-2717, 2023

Recent advancements in the B7/CD28 immune checkpoint families: New biology and clinical therapeutic strategies 

Pulanco MC, Madsen AT, Tanwar A, Corrigan DT, Zang X.

Cellular & Molecular Immunology, 20:694-713, 2023

Heterogeneous expression of PD-L1, B7x, B7-H3, and HHLA2 in pulmonary sarcomatoid carcinoma and the related regulatory signaling pathways 

Wang F, Daylan AEC, Deng L, Yang J, Sharma J, Su C, Li S,  Zang X, Halmos B, Borczuk A, Cheng H.

Cancers, 15:3372, 2023

Blockade of the immunosuppressive KIR2DL5-PVR pathway elicits potent human NK cell-mediated anti-tumor immunity

Ren X, Peng M, Xing P, Wei Y, Galbo PM, Corrigan D, Wang H, Su Y, Dong X, Sun Q, Li Y, Zhang X, Edelmann W, Zheng D, Zang X.

Journal of Clinical Investigation, 132:e163620. doi: 10.1172/JCI163620, 2022

The immune checkpoint B7x expands tumor-infiltrating regulatory T cells and promotes resistance to anti-CTLA-4 therapy

John P, Pulanco MC, Galbo PM, Wei Y, Ohaegbulam KC, Zheng D, Zang X.

Nature Communications, 13:2506. doi: 10.1038/s41467-022-30143-8, 2022

The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development

Picarda E, Galbo PM, Zong H, Rajan MR, Wallenius V, Zheng D, Borgeson E, Singh R, PessinJ, Zang X.

Science Advances, 8:eabm7012, 2022

Protocol for evaluating anti-tumor activity of KIR3DL3 blockade in an NK cell-based xenogeneic lung tumor model 

Ren X, Corrigan D, Zang X.

STAR Protocols, 3:101818. doi: 10.1016/j.xpro, 2022

Crosstalk between the B7/CD28 and EGFR pathways: Mechanisms and therapeutic opportunities

Ren X, Li Y, Nishimura C, Zang X.

Genes & Diseases, 9:1181-1193, 2022

Potentiating effect of reovirus on immune checkpoint inhibition in microsatellite stable colorectal cancer 

Augustine T, John P, Friedman T, Jiffry J, Guzik H, Mannan R, Gupta R, Delano C, Mariadason J, Zang X, Maitra R, Goel S .

Frontiers in Oncology,  12:1018767. doi: 10.3389/fonc.2022.1018767, 2022

KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target

Wei Y, Ren X, Galbo PM, Moerdler S, Wang H, Sica RA, Etemad-Gilbertson B, Shi L, Zhu L,Tang X, Lin Q, Peng M, Guan F, Zheng D, Chinai JM, Zang X.

Science Immunology, 6:eabf9792, 2021

PD-L1 and B7-1 cis-interaction: New mechanisms in immune checkpoints and immunotherapies

Nishimura CD, Pulanco MC, Cui W, Lu L, Zang X.

Trends in Molecular Medicine, 27:207-219, 2021

Molecular features of cancer-associated fibroblast subtypes and their Implication on cancer pathogenesis, prognosis, and immunotherapy resistance

Galbo PM, Zang X*, Zheng D*.

Clinical Cancer Research, 27:2636-2647, 2021

Tissue-resident macrophages promote multiple myeloma early dissemination and progression via IL-6 and TNFa

Akhmetzyanova I, Aaron T, Galbo P, Tikhonova A, Dolgalev I, Tanaka M, Aifantis I, Zheng D, Zang X, Fooksman DR.

Blood Advances, 5:3592-3608, 2021

B7 score and T cell infiltration stratified immune status in prostate cancer

Zhou QH, Li KW, Lai YM, Yao K, Wang Q, Zhan XY, Peng SR, Cai WI, Wei Y, Zang X, Xu KW,Huang J, Huang H

Journal for ImmunoTherapy of Cancer, 9: e002455, 2021

B7 immune-checkpoints as targets for the treatment of neuroendocrine tumors

Yuan Z, Gardiner J, Maggi EC, Huang S, Adem A, Li G, Lee S, Howe JR, Lattime E, Zang X, Libutti SK

Endocrine-Related Cancer, 28:135-149, 2021

Patterns of leukocyte recovery predict infectious complications after CD19 CAR-T cell therapy in a real-world setting

        Thakkar A, Cui Z, Peeke SZ, et al.

             Stem Cell Investigation, 8:18. doi: 10.21037/sci-2021-008, 2021

LAG-3 is expressed on a majority of tumor filtrating lymphocytes in pediatric Hodgkin lymphoma

Moerdler S, Ewart M, Friedman DL, Kelly K, Pei Q, Peng M, Zang X, Cole P

Leukemia and Lymphoma, 62:606-613, 2021

B7-H3 and PD-L1 expression are prognostic biomarkers in a multi-racial cohort of patients with colorectal cancer

Zhang W, Acuna-Villaorduna A, Kuan K, Gupta S, Hu S, Ohaegbulam K, Albanese J, KaumayaM, Levy R, Hwang RR, Zang X, Lin J, Liu Q, Maitra R, Goel S

Clinical Colorectal Cancer, 20:161-169, 2021

HHLA2 is expressed in pancreatic and ampullary cancers and increased expression is associated with better post-surgical prognosis

Boor PPC, Sideras K, Biermann K, Levink IJM, Mancham S, Erler N, Tang X, van Eijck CH,Bruno MJ, Sprengers D, Zang X, Kwekkeboom J.

British Journal of Cancer, 122:1211–1218, 2020

Over-expression and prognostic significance of HHLA2, a new immune checkpoint, inhuman clear cell renal cell carcinoma

Zhang Z, Liu J, Zhang C, Li F, Li L, Wang D, Qiao Y, Chand D, Guan F, Zang X*, Zhang Y*.

Frontiers in Cell and Developmental Biology, 8:280. doi: 10.3389/fcell.2020.00280, 2020

Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer

Li Y, Liu Y, Zhao N, Yang X, Li Y, Zhai F, Zang X*, Cui W*.

Cell Death and Disease, 11:753. doi: 10.1038/s41419-020-02968-y, 2020

The B7x immune checkpoint pathway: From discovery to clinical trial

John P, Wei Y, Liu W, Du M, Guan F, Zang X

Trends in Pharmacological Sciences, 40:883-896, 2019

Tumor cholesterol up, T cells down

Picarda E, Ren X, Zang X

Cell Metabolism, 30:12-13, 2019

Structures of immune checkpoints: An overview on the CD28-B7 Family

Liu W, Zang X

Structural Immunology, Springer, 63-78, 2019

Donor and host B7-H4 expression negatively regulates acute graft-versus-host disease lethality

Saha A, Taylor PA, Lees CJ, Panoskaltsis-Mortari A, Osborn MJ, Feser CJ, Thangavelu G,Melchinger W, Refaeli Y, Hill GR, Munn DH, Murphy WJ, Serody JS, Maillard I, Kreymborg K,van den Brink M, Dong C, Huang S, Zang X, Allison JP, Zeiser R, Blazar BR.

JCI Insight, 4(19). pii: 127716. doi: 10.1172/jci.insight.127716, 2019

Rapid progression of adult T-cell leukemia/lymphoma as tumor infiltrating Tregs after PD-1 blockade

Rauch DA, Conlon KC, Janakiram M, Brammer JE, Harding JC, Ye BH, Zang X, Ren X, OlsonS, Cheng X, Miljkovic MD, Sundaramoorthi H, Joseph A, Skidmore ZL, Griffith O, Griffith M,Waldmann TA, Ratner L.

Blood, 134:1406-1414, 2019

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies

Wang H, Kaur G, Sankin AI, Chen F, Guan F, Zang X.

Journal of Hematology & Oncology, 12:59. doi: 10.1186/s13045-019-0746-1, 2019

Human urothelial bladder cancer generates a clonal immune response: The results of T-cell receptor sequencing

Sankin A, Chand D, Schoenberg M, Zang X.

Urologic Oncology, 37:810.e1-810.e5. doi: 10.1016/j.urolonc.2019.04.011, 2019

Fibronectin regulation of integrin B1 and SLUG in circulating tumor cells

Huaman J, Naidoo M, Zang X, Ogunwobi OO.

      Cells, 8:618. doi: 10.3390/cells8060618, 2019

Immune checkpoint B7x(B7-H4/B7S1/VTCN1) is over expressed in spontaneous Canine bladder cancer: The first report and its implications as a preclinical model

Chand D, Dhawan D, Sankin A, Ren X, Lin J, Schoenberg M, Knapp DW, Zang X.

Bladder Cancer, 5:63-71, 2019

PAK kinase inhibition has therapeutic activity in novel preclinical models of Adult T-cell Leukemia/Lymphoma

Chung EY, Mai Y, Shah UA, Wei Y, Ishida E, Kataoka K, Ren X, Pradhan K, Bartholdy B, WeiX, Zou Y, Zhang J, Ogawa S, Steidl U, Zang X, Verma A, Janakiram M, B. Ye BH

Clinical Cancer Research, 25:3589-3601, 2019

Cell-cell contact with proinflammatory macrophages enhances the immunotherapeutic effect by mesenchymal stem cells in two abortion models

Lin Y, Zhang D, Xu L, Dong L, Lin Y, Huang J, Zhang Y, Tao Y, Zang X, Li DJ, Zheng J, Du M

Cellular and Molecular Immunology, 16:908-920. 2019

Blockade of CTLA-4 and Tim-3 pathways induce fetal loss with altered cytokine profiles by decidual CD4+T cells

Wang S, Chen C, Li M, Qian J, Sun F, Lin Y, Yu M, Wang M, Zang X, Zhu R, Li D, Du M.

Cell Death and Disease, 10:15. doi: 10.1038/s41419-018-1251-0, 2019

The appropriate frequency and function of decidual Tim-3+CTLA-4+CD8+T cells are important in maintaining normal pregnancy

Wang S, Sun F, Li M, Qian J, Chen C, Wang MY, Zang X, Li DJ, Yu M, Du M.

Cell Death and Disease, 10(6):407. doi: 10.1038/s41419-019-1642-x, 2019

2018 Nobel Prize in Medicine awarded to cancer immunotherapy: Immune checkpoint blockade – A personal account

Zang X.

Genes & Diseases, 5:302-303, 2018

PD-1/PDL-1 inhibitors as immunotherapy for ovarian cancer

Moerdler S, Zang X

Ovarian Cancer Immunotherapy, Oxford University Press, 170-192, 2018

Wide expression and significance of alternative immune checkpoint molecules, B7x andHHLA2, in PD-L1 negative human lung cancers

Cheng H*, Borczuk A, Janakiram M, Ren X, Lin J, Assal A, Halmos B, Perez-Soler R, Zang X*.

Clinical Cancer Research, 24:1954-1964, 2018

NF-kB RelA renders tumor-associated macrophages resistant to and capable of directly suppressing CD8+ T cells for tumor promotion

Li L, Han L, Sun F, Zhou J, Ohaegbulam KC, Tang X, Zang X, Steinbrecher KA, Qu Z, Xiao G.

OncoImmunology, 7:e1435250-13, 2018

PD-L1 expression is a prognostic factor in subgroups of gastric cancer patients stratified according to their levels of CD8 and Foxp3 immune markers

Ying L, Yan F, Meng Q, Yu L, Yuan X, Gantier MP, Williams BRG, Chan DW, Shi L, Tu Y, NiP,Wang X, Chen W, Zang X, Xu D, Hu Y.

OncoImmunology, 7:e1433520-11, 2018

Tumor-expressed immune checkpoint B7x promotes cancer progression and antigen-specific CD8 T cell exhaustion and suppressive innate immune cells

Ohaegbulam KC, Liu W, Jeon H, Almo SC, Zang X.

Oncotarget, 8:82740-82753, 2017

An immunoscore using PD-L1, CD68 and tumor–infiltrating lymphocytes (TILs) to predict response to neoadjuvant chemotherapy in invasive breast cancer

McLemore LE, Janakiram M, Albanese J, Shapiro N, L Y, Zang X. Fineberg S.

Applied Immunohistochemistry & Molecular Morphology, 26:611-619, 2018

The expanding repertoire of targets for immune checkpoint inhibition in bladder cancer: what lies beneath the tip of the iceberg, PD-L1

Sankin A, Narasimhulu D, John P, Gartrell B, Schoenberg M, Zang X.

Urologic Oncology, 36:459-468, 2018

The third group of the B7-CD28 immune checkpoint family: HHLA2, TMIGD2, B7x and B7-H3

Janakiram M, Shah UA, Liu W, Zhao A, Schoenberg MP, Zang X.

Immunological Reviews, 276:26-39, 2017

A review of the PD-1/PD-L1 checkpoint in bladder cancer: from mediator of immune escape to target for treatment

Zhou TC, Sankin AI, Porcelli SA, Perlin DS, Schoenberg MP, Zang X.

Urologic Oncology, 35:14-20, 2017

HHLA2, a new immune checkpoint member of the B7 family, is widely expressed in human lung cancer and associated with EGFR mutational status

Cheng H*, Janakiram M, Borczuk A, Lin J, Qiu W, Liu H, Chinai JM, Halmos B, Perez-Soler R, Zang X*.

Clinical Cancer Research, 23:825-832, 2017

HHLA2, a member of the B7 family, is expressed in human osteosarcoma and is associated with metastases and worse survival

Koirala P, Roth M, Gill J, Chinai J, Ewart M, Piperdi S, Geller D, Hoang B, Fatakhova K,Ghorpade M, Zang X*, Gorlick R*.

Scientific Reports, 6:31154. doi: 10.1038/srep31154, 2016

Molecular pathways: Targeting B7-H3 (CD276) for human cancer immunotherapy

Picarda E, Ohaegbulam KC, Zang X.

Clinical Cancer Research, 22:3425-3431, 2016

Tumor infiltrating lymphocytes as a prognostic and predictive biomarker in breast cancer

Janakiram M, Khan H, Fineberg S, Zang X, Sparano JA.

Molecular Pathology of Breast Cancer, Springer, 167-186, 2016

Immune infiltration and PD-L1 expression in the tumor microenvironment are prognostic in osteosarcoma

Koirala P, Roth M, Gill J, Piperdi S, Chinai J, Geller D, Hoang B, Park A, Fremed M, Zang X, Gorlick R.

Scientific Reports, 6:30093. doi: 10.1038/srep30093, 2016

Immune checkpoint blockade in human cancer therapy: Lung cancer and hematopoietic malignancy

Janakiram M, Pareek V, Cheng H, Narasimhulu D, Zang X.

Immunotherapy, 8:809-819, 2016

Co-stimulate or co-inhibit regulatory T cells, which side to go?

Liu W, Almo SC, Zang X.

Immunological Investigations, 45:813-831, 2016

B7-H4(B7x)-mediated cross-talk between glioma-initiating cells and macrophages via theIL-6/JAK/STAT3 pathway lead to poor prognosis in glioma patients

Yao Y, Ye H, Qi Z, Mo L, Yue Q, Baral A, Hoon DSB, Vera JC, Heiss JD, Chen CC, Hua W,Zhang J, Jin K, Wang Y, Zang X*, Mao Y*, Zhou L*

Clinical Cancer Research, 22:2778-2790, 2016

Emerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1

Assal A, Kaner J, Pendurti G, Zang X.

Immunotherapy, 7:1169-1186, 2015

New immunotherapies targeting the PD-1 pathway

Chinai JM, Janakiram M, Chen F, Chen W, Kaplan M, Zang X.

Trends in Pharmacological Sciences, 36:587-595, 2015

The T-cell inhibitory molecule Butyrophilin-like 2 is up-regulated in mild Plasmodium falciparum infection and is protective during experimental cerebral malaria

Subramaniam KS, Spaulding E, Ivan E, Mutimura E, Kim R, Liu X, Dong C, Feintuch CM, ZangX, Anastos K, Lauvau G, Daily JP.

Journal of Infectious Diseases, 212:1322–31, 2015

HHLA2 and TMIGD2: New immunotherapeutic targets of the B7 and CD28 families

Janakiram M, Chinai JM, Zhao A, Sparano JA, Zang X.

OncoImmunology, 4: e1026534-1 - e1026534-3, 2015

Substituting threonine187 with alanine in p27Kip1 prevents pituitary tumorigenesis by two-hit loss of Rb1 and enhances humoral immunity in old age

Zhao H, Bauzon F, Bi E, Yu JJ, Fu H, Lu Z, Cui J, Jeon H, Zang X, Ye BH, Zhu L.

Journal of Biological Chemistry, 290:5797-5809, 2015

Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway

Ohaegbulam KC, Assal A, Lazar-Molnar E, Yao Y, Zang X.

Trends in Molecular Medicine, 21:24-33, 2015

B7x/B7-H4 modulates the adaptive immune response and ameliorates renal injury in antibody mediated nephritis

Pawar RD, Goilav B, Xia Y, Herlitz L, Doerner J, Chalmers S, Ghosh K, Zang X, Putterman C.

Clinical & Experimental Immunology, 179:329-343, 2014

Expression, clinical significance, and receptor identification of the newest B7 family member HHLA2 protein

Janakiram M, Chinai JM, Fineberg S, Fiser A, Montagna C, Medaverepu R, Castano E, JeonH, Ohaegbulam KC, Zhao R, Zhao A, Almo SC, Sparano JA, Zang X.

Clinical Cancer Research, 21:2359-2366, 2015

Structure and cancer immunotherapy of the B7 family member B7x

Jeon H, Vigdorovich V, Garrett-Thomson SC, Janakiram M, Ramagopal UA, Abadi YM, Lee JS,Scandiuzzi L, Ohaegbulam KC, Chinai JM, Zhao R, Yao Y, Mao Y, Sparano JA, Almo SC, ZangX.

Cell Reports, 9:1089-1098, 2014

Tissue-expressed B7-H1 (PD-L1) critically controls intestinal inflammation

Scandiuzzi L, Ghosh K, Hofmeyer KA, Abadi YM, Lázár-Molnár E, Lin EY, Liu Q, Jeon H, AlmoSC, Chen L, Nathenson SG, Zang X.

Cell Reports, 6:625-632, 2014

The B7 and CD28 families

Zang X.

Encyclopedia of Medical Immunology, I.R.Mackay and N.R. Rose, ed. Springer, 174-181, 2014

HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T cell function

Zhao R, Chinai JM, Buhl S, Scandiuzzi L, Ray A, Jeon H, Ohaegbulam KC, Ghosh K, Zhao A,Scharff MD, Zang X.

Proceedings of the National Academy of Sciences USA, 110:9879-9884, 2013

Curcumin improves the therapeutic efficacy of Listeria-Mage-b vaccine in correlation withimproved T cell responses in blood of a triple negative breast cancer model 4T1

Singh M, Ramos L, Asafu-Adjei D, Quispe-Tintaya W, Chandra D, Jahangir A, Zang X, Aggarwal BB, Gravekamp C

Cancer Medicine, 2:571-582, 2013

B7x and myeloid derived suppressor cells in the tumor microenvironment: A tale of two cities

Jeon H, Ohaegbulam KC, Abadi YM, Zang X.

OncoImmunology, e24744-1-e24744-3, 2013

Structure and T cell coinhibition properties of B7 family member B7-H3

Vigdorovich V, Ramagopal U, Lazar-Molnar E, Sylvestre E, Lee JS, Hofmeyer KA, Zang X, Nathenson SG, Almo SC.

Structure, 21:707-717, 2013

Host B7x promotes pulmonary metastasis of breast cancer

Abadi YM, Jeon H, Ohaegbulam KC, Scandiuzzi L, Ghosh K, Hofmeyer KA, Lee JS, Ray A,Gravekamp C, Zang X.

Journal of Immunology, 190:3806-3814, 2013

T cell coinhibition and immunotherapy in human breast cancer

Janakiram M, Abadi YM, Sparano JA, Zang X.

Discovery Medicine, 14:229-236, 2012

B7x in the periphery abrogates pancreas specific damage mediated by self-reactive CD8 T cells

Lee JS, Scandiuzzi L, Ray A, Wei J, Hofmeyer KA, Abadi MY, Loke P, Lin J, Yuan J, SerrezeDV, Allison JP, Zang X.

Journal of Immunology, 189:4165-4174, 2012

Tissue-expressed B7x affects the immune response to and outcome of lethal pulmonary infection

Hofmeyer KA, Scandiuzzi L, Ghosh K, Pirofski LA, Zang X.

Journal of Immunology, 189:3054-3063, 2012

T cell costimulation and coinhibition: Genetics and disease

Scandiuzzi L, Ghosh K, Zang X.

Discovery Medicine, 12:119-128, 2011

The PD-1/PD-L1 (B7-H1) pathway in chronic infection-induced cytotoxic T lymphocyte exhaustion

Hofmeyer KA, Jeon H, Zang X.

Journal of Biomedicine and Biotechnology, 2011:451694, 2011

Tissue specific expression of B7x protects from CD4 T cell mediated autoimmunity

Wei J, Loke P, Zang X*, Allison JP*.

Journal of Experimental Medicine, 208:1683-1694, 2011

T cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics

Barach YS, Lee JS, Zang X.

Trends in Molecular Medicine, 17:47-55, 2011

Tumor associated endothelial expression of B7-H3 predicts survival in ovarian carcinomas

Zang X, Sullivan PS, Soslow RA, Waitz R, Reuter VE, Wilton A, Thaler HT, Arul M, Slovin SF,Wei J, Spriggs DR, Dupont J, Allison JP.

Modern Pathology, 23:1104-1112, 2010

Mouse Mast cell protease-4 deteriorates renal function by contributing to inflammation and fibrosis in immune complex-mediated glomerulonephritis

Scandiuzzi L, Beghdadi W, Daugas E, Abrink M, Tiwari N, Brochetta C, Claver J, Arouche N, Zang X, Pretolani M, Monteiro RC, Pejler G, Blank U.

Journal of Immunology, 185:624-633, 2010

The contrasting role of B7-H3

Hofmeyer KA, Ray A, Zang X.

Proceedings of the National Academy of Sciences USA, 105: 10277-10278, 2008

Serum soluble B7x is elevated in renal cell carcinoma patients and is associated with advanced stage

Thompson RH*, Zang X*, Lohse CM, Leibovich BC, Slovin S, Reuter VE, Blute ML, Russo P, Kwon ED, Allison JP.

Cancer Research, 68: 6054-6058, 2008

The B7 family and cancer therapy: Costimulation and coinhibition

Zang X, Allison JP.

Clinical Cancer Research, 13: 5271-5279, 2007

B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome

Zang X*, Thompson RH*, Al-Ahamadie A, Serio AM, Reuter VE, Eastham JA, Scardino PT,Sharma P, Allison JP.

Proceedings of the National Academy of Sciences USA, 104: 19458-19463, 2007

T cell immunoglobulin mucin-3 crystal structure reveals a galectin-9-independent ligand-binding surface

Cao E*, Zang X*, Ramagopal UA*, Mukhopadhaya A, Fedorov A, Fedorov E, Zencheck WD,Lary JW, Cole JL, Deng H, Xiao H, DiLorenzo TP, Allison JP, Nathenson SG, Almo SC.

Immunity, 26: 311-321, 2007

Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic Infection

Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE.

Journal of Immunology, 179: 3926-3936, 2007

To be or not to be B7

Zang X, Allison JP.

Journal of Clinical Investigation, 116: 2590-2593, 2006

A genetic library screen for signaling proteins that interact with phosphorylated T cell costimulatory receptors

Zang X, Loke P, Kim J, Wojnoonski K, Kusdra L, Allison JP.

Genomics, 88: 841-845, 2006

Inducible costimulator is required for type 2 antibody isotype switching but not T helper cell type 2 responses in chronic nematode infection

Loke P, Zang X, Hsuan L, Waitz R, Locksley RM, Allen IE, Allison JP.

Proceedings of the National Academy of Sciences USA, 102: 9872-9877, 2005

BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1

Watanabe N, Gavrieli M, Sedy JR, Yang J, Fallarino F, Loftin SK, Hurchla MA, Zimmerman N,Sim J, Zang X, Murphy TL, Russell JH, Allison JP, Murphy KM.

Nature Immunology, 4:670-679, 2003

B7x: A widely expressed B7 family member that inhibits T cell activation

Zang X, Loke P, Kim J, Murphy K, Waitz R, Allison JP.

Proceedings of the National Academy of Sciences USA, 100: 10388-10392, 2003

Cloning and characterisation of mmc-1, a microfilarial-specific gene, from Brugia pahangi

Emes R, Thompson F, Moore J, Zang X, Devaney E.

International Journal for Parasitology, 32:415-424, 2002

Homologues of human macrophage migration inhibitory factor from a parasitic nematode: Gene cloning, protein activity, and crystal structure

Zang X, Taylor P, Wang JM, Meyer DJ, Scott AL, Walkinshaw MD, Maizels RM.

Journal of Biological Chemistry, 277:44261-44267, 2002

A Brugia malayi homolog of macrophage migration inhibitory factor reveals an important link between macrophages and eosinophil recruitment during nematode infection

Falcone FH, Loke P, Zang X, MacDonald AS, Maizels RM, Allen JE.

Journal of Immunology, 167: 5348-5354, 2001

Immune evasion genes from filarial nematodes

Maizels RM, Gomez-Escobar N, Gregory WF, Murray J, Zang X.

International Journal for Parasitology, 31:889-898, 2001

Serine proteinase inhibitors from nematodes and the arms race between host and pathogen

Zang X, Maizels RM.

Trends in Biochemical Sciences, 26:191-197, 2001

The serpin secreted by Brugia malayi microfilariae, Bm-SPN-2, elicits strong but short-lived immune responses in mice and humans

Zang X, Atmadia KA, Gray P, Allen JE, Gray CA, Lawrence RA, Yazdanbakhsh M, Maizels RM.

Journal of Immunology, 165:5161-5169, 2000

Vaccination against helminth parasites: the ultimate challenge for vaccinologists?

Maizels RM, Holland M, Falcone F, Zang X, Yazdanbakhsh M.

Immunological Reviews, 171:125-147, 1999

A novel serpin expressed by blood-borne microfilariae of the parasitic nematode Brugia malayi inhibits human neutrophil serine proteinases

Zang X, Yazdanbakhsh M, Jiang HB, Kanost MR, Maizels RM.

Blood, 94:1418-1428, 1999